# To Evaluate the Efficacy and Safety of Co-administrated Ezetimibe/Rosuvastatin and Telmisartan in Patients With Essential Hypertension and Primary Hypercholesterolemia

Study · id `cardio:ct-nct04659070` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04659070](<https://clinicaltrials.gov/study/NCT04659070>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04659070

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 156 participants.

## Technical summary

Registry record NCT04659070. Randomized; triple masking; primary purpose treatment. Start 2020-07-15 (actual); primary completion 2022-05-19 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 156 participants (planned count; ClinicalTrials.gov record NCT04659070, source copy `cardio:ctgov-nct04659070-2020-12-09`, retrieved 2026-10-26)
- Started: 2020-07-15 (actual) (ClinicalTrials.gov record NCT04659070, source copy `cardio:ctgov-nct04659070-2020-12-09`, retrieved 2026-10-26)
- Primary completion: 2022-05-19 (anticipated) (ClinicalTrials.gov record NCT04659070, source copy `cardio:ctgov-nct04659070-2020-12-09`, retrieved 2026-10-26)
- Completion: 2022-05-19 (anticipated) (ClinicalTrials.gov record NCT04659070, source copy `cardio:ctgov-nct04659070-2020-12-09`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT04659070, source copy `cardio:ctgov-nct04659070-2020-12-09`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04659070-2020-12-09`, retrieved 2026-10-26)

## The registry's words

- Brief title: To Evaluate the Efficacy and Safety of Co-administrated Ezetimibe/Rosuvastatin and Telmisartan in Patients With Essential Hypertension and Primary Hypercholesterolemia
- Condition: Primary Hypercholesterolemia
- Condition: Hypertension
- Intervention (Drug): Experimental : Ezetimibe / Rosuvastatin + Telmisartan
- Intervention (Drug): Active comparator1 : Ezetimibe / Rosuvastatin
- Intervention (Drug): Active comparator2 : Telmisartan
- Lead sponsor: Hanlim Pharm. Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Hanlim Pharm. Co., Ltd. (`cardio:org-hanlim-pharm-co-ltd`)

## Provenance

Content hash: cd1b09f8158353b3f74ce294ca1cab0c37017c0c0d1cc893b0c42c0d17fa8c16
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
